Guest guest Posted June 29, 2006 Report Share Posted June 29, 2006 Political Economy of AIDS Vaccine Trial in India The Indian AIDS Vaccine researchers need to be more forthcoming in disclosing the commercial details of the deal between the Targeted Genetics and Indian Council of Medical Research (ICMR) brokered by International AIDS Vaccine Initiative (IAVI). It appears that the full commercial details of the AIDS Vaccine trial brokered by IAVI for the US Pharmaceutical company, Targeted Genetics is not yet disclosed to the Indian public. Such a public disclosure is particularly important as Mr. Kapil Sibal, Minister of Science and Technology, and Ocean Development, Government of India is on the board of directors of IAVI. Repeated call for a " White paper " on AIDS Vaccine trials engineered by IAVI in India has been ignored by the Indian office of the IAVI so far. The Targeted Genetics Corporation has entered into a collaboration and license agreement with the International Aids Vaccine Initiative (IAVI) and its collaborators, in support of the development and commercialization of HIV/AIDS vaccines. The new agreement supersedes a previous collaboration agreement entered into by Targeted Genetics, IAVI and its partners in 2000. According to the information from the Targeted Genetics, the vaccine candidate, tgAAC09, utilizes a recombinant adeno-associated viral vector (AAV) that was developed with and manufactured by Targeted Genetics. IAVI is funding development, pre-clinical and clinical studies to test the vaccine, including the clinical trials in India. The Targeted Genetics' AAV manufacturing process is based on a cell line which was designed by Dr. Philip R. . As an immediate response to the announcement of AIDS Vaccine trial in India, the stock value of Targeted genetics (Nasdaq:TGEN) has increased 5.78%. Knowingly or unknowingly, what ICMR is doing is just a contract research for IAVI. " To date, IAVI has substantially funded Targeted Genetics' HIV/AIDS vaccine program efforts, significantly exceeding IAVI's initial funding commitment made to the program in 2000. Says the information released of the US share holders of Targeted genetics Under this new agreement, Targeted Genetics expects to continue to receive significant funding from IAVI for the continued development of HIV/AIDS vaccines for the developing world. Targeted Genetics also received the rights to utilize the findings from the IAVI funded program to develop and commercialize HIV/AIDS vaccines for both the developed world and for any additional vaccine candidates. Among other rights granted under the agreement, between IAVI and Targeted Genetics, IAVI retains the exclusive rights for commercialization in the developing world of any HIV/AIDS vaccine that is developed under the collaboration, and will receive a royalty on income received by Targeted Genetics from the development and commercialization of vaccines. Targeted Genetics will also issue company shares to IAVI. Among other rights granted under this agreement, IAVI retains the exclusive rights for commercialization in the developing world of any HIV/AIDS vaccine that is developed under the collaboration, and will receive a royalty on income received by Targeted Genetics from the development and commercialization of vaccines. Targeted Genetics will also issue IAVI a small number of shares of its common stock It may be appropriate for Dr.P.R. Narayanan, Director, Tuberculosis Research Centre (TRC) an Indian Council of Medical Research (ICMR) institute who is conducting the vaccine trial in Chennai, and Dr. V.Ramanathan, principal investigator of the trial to disclose their conflict of interest in this trial . Are they aware of the commercial details of the AIDS vaccine trial in India? TRC collaborates with YRG Care and the International AIDS Vaccine Initiative on the project, conservatively estimated to cost at least one million USD and expected to reap disproportionate financial benefits for the Targeted Genetics and IAVI. The ethics review committee members of Indian IAVI AIDS Vaccine research needs to be much more proactive in understanding the ethical issues of commercial details of the vaccines trial contract in India as well. IAVI need to be more forth coming in disclosing their commercial interest in the clinical trial in India. Any reluctance to disclose the commercial details of the AIDS Vaccine trial in India is unethical. For the sake of transparency, and accountability IAVI must release a " White paper " on AIDS Vaccine trial in India. Joe Moderator AIDS INDIA eFORUM / Reference: Targeted Genetics Enters into New Agreement with the International Aids Vaccine Initiative to Support Its Ongoing HIV/AIDS Vaccine Development Program.28.06.2006 11:30:00 http://finanzen.net/news/news_detail.asp?NewsNr=409964 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.